LIXT News and Press, Lixte Biotechnology Holdings Inc.

2026-02-23 09:05:00 ET LIXTE has acquired Liora Technologies Europe Ltd., securing its proprietary LiGHT system for advanced proton therapy treatment Liora works at the forefront of electronically controlled proton beam innovation, with its platform installed at the UK’s STFC D...

2026-02-18 09:55:00 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) , a clinical-stage pharmaceutical and med-tech company advancing cancer treatments, announced the appointment of Sidney Braun as Chief Executive Officer of its Liora Technologies Europe Ltd. subsidiary. Braun, who pr...

BOCA RATON, Fla., Feb. 18, 2026 (GLOBE NEWSWIRE) -- LIXTE Biotechnology Holdings, Inc. (“LIXTE” or the “Company”) (Nasdaq: LIXT), a clinical stage pharmaceutical and med-tech company focused on advancing cancer treatments, today announced it has appointed Sidney Braun...

2026-02-13 09:50:00 ET LIXTE recently announced advances in its approach to cancer therapy through its proprietary compound LB-100 Alongside clinical development news, LIXTE is sponsoring the Good Health: Mind, Body & Soul Summit These two announcements paint a pictu...

2026-02-11 14:45:28 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) , a clinical-stage pharmaceutical company, is focused on enhancing established cancer therapies by targeting a fundamental biological pathway involved in tumor survival and resistance. “Rather than developing stan...

2026-02-09 09:50:00 ET LIXTE Biotechnology recently acquired Liora Technologies, and the acquisition includes Liora’s proprietary LiGHT system This system provides several advantages over technologies that are currently available for treating tumors with proton therapy The ...

2026-02-06 15:09:02 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) , a clinical-stage pharmaceutical company, is leading efforts in addressing some of the pressing challenges in cancer treatment. “Instead of developing standalone cancer drugs, the company is adopting a different ...

2026-02-04 11:20:00 ET LIXTE’s lead compound, LB-100, targets PP2A, a central regulator of cancer cell survival and treatment resistance Clinical programs are designed to enhance existing immunotherapies and chemotherapies rather than replace them Multiple active trials acr...

2026-01-22 09:50:00 ET LIXTE is developing a first-in-class therapy designed to enhance the effectiveness of existing cancer treatments Its lead compound, LB-100, targets PP2A and is advancing through multiple clinical trials with a favorable safety profile The company is building...

2026-01-21 09:46:26 ET LIXTE Biotechnology Holdings (NASDAQ: LIXT) is sponsoring the inaugural Good Health: Mind, Body & Soul Summit, an invitation-only event inspired by the music, legacy, and lived experiences of De La Soul and scheduled for Feb. 19 at Morehouse College in Atl...